Control of Hypertension In Pregnancy Study
Go to the Dutch website. Here you can find:
- Sample patient information / informed consent
- All data forms and Dutch Working Protocol
Go to the Canadian website. Here you can find:
- English protocol
- Pilot publications
- Information about meetings
Office dBP 90-105mmHg (or dBP 85-105mmHg if on antihypertensive medication)
Gestational age between 14 and 33+6 weeks
Severe systolic hypertension
Contraindication to either arm of trial or to prolongation of pregnancy
ACE inhibitor use in pregnancy at 14 or more weeks of gestation
Known multiple gestation or lethal/major fetal anomaly
Plan to terminate pregnancy
Prior participation in CHIPS
Randomisation will be stratified by centre and type of hypertension (pre-existing or gestational). In the ‘less tight’ control group, if dBP is = 105mmHg, then antihypertensive medication must be started or increased in dose. In the ‘tight’ control group, if dBP is = 80mmHg, then antihypertensive medication must be decreased in dose or discontinued.
Both groups: Centres will provide their usual care. Data will be collected on potential co-interventions (e.g., hospitalisation, bed-rest).
Pregnancy loss (miscarriage, pregnancy termination, stillbirth, or neonatal death) or NICU admission for >48hr in the first 28 days of life or prior to primary hospital discharge, whichever is later.
One/more serious maternal complication(s) until six weeks postpartum
(J Clin Epidemiol 2004;57(5):454-60’214).
Will be performed by Canadian CHIPS study group.
Recruitment during a 4 year period from April 2009.
Dr Wessel Ganzevoort, Academic Medical Center
Prof Dr Joris van der Post, Academic Medical Center
Prof Dr Ben Willem Mol, Academic Medical Center
Health Technology Assessment
Canadian Institute of Health Research
Dr Wessel Ganzevoort, Room H4-205, POBox 22660 1100 DD Amsterdam